- Home
- SRG vs VNDA Comparison
SRG vs VNDA Comparison
Compare SRG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- VNDA
- Stock Information
- Founded
- SRG 2014
- VNDA 2002
- Country
- SRG United States
- VNDA United States
- Employees
- SRG N/A
- VNDA N/A
- Industry
- SRG Real Estate Investment Trusts
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- VNDA Health Care
- Exchange
- SRG Nasdaq
- VNDA Nasdaq
- Market Cap
- SRG 237.7M
- VNDA 249.4M
- IPO Year
- SRG 2015
- VNDA 2006
- Fundamental
- Price
- SRG $4.06
- VNDA $5.27
- Analyst Decision
- SRG
- VNDA Strong Buy
- Analyst Count
- SRG 0
- VNDA 2
- Target Price
- SRG N/A
- VNDA $16.50
- AVG Volume (30 Days)
- SRG 96.5K
- VNDA 567.7K
- Earning Date
- SRG 11-11-2025
- VNDA 11-05-2025
- Dividend Yield
- SRG N/A
- VNDA N/A
- EPS Growth
- SRG N/A
- VNDA N/A
- EPS
- SRG N/A
- VNDA N/A
- Revenue
- SRG $15,346,000.00
- VNDA $203,467,000.00
- Revenue This Year
- SRG N/A
- VNDA $15.45
- Revenue Next Year
- SRG N/A
- VNDA $37.82
- P/E Ratio
- SRG N/A
- VNDA N/A
- Revenue Growth
- SRG N/A
- VNDA 11.78
- 52 Week Low
- SRG $2.43
- VNDA $3.81
- 52 Week High
- SRG $4.72
- VNDA $5.59
- Technical
- Relative Strength Index (RSI)
- SRG 51.89
- VNDA 58.91
- Support Level
- SRG $3.88
- VNDA $5.16
- Resistance Level
- SRG $4.21
- VNDA $5.54
- Average True Range (ATR)
- SRG 0.17
- VNDA 0.22
- MACD
- SRG -0.04
- VNDA -0.01
- Stochastic Oscillator
- SRG 41.94
- VNDA 61.33
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.